Preliminary financial results of the statutory health insurance for 2020 in Germany

02

Apr 2021

According to the available financial results, published by the German Federal Ministry of Health,  the German statutory health insurance companies reported a total deficit of around 2.65 billion euros in 2020. The health fund reported a deficit of 3.49 billion euros in 2020. As of January 15, 2021, the health fund's liquidity reserve was around 5.9 billion euros.

The income of the health insurance companies, which they receive primarily through pre-determined allocations from the health fund, rose by 4.0% to 260 billion euros. Expenditures for services and administrative costs also demonstrated an increase of 4.0% to 262.6 billion euros with an increase in the number of insured persons of 0.3%.

With the exception of the LKK, all other health insurance companies reported a deficit in the past year: AOK - 974 million euros, BKK - 235 million euros, IKK - 250 million euros, and Knappschaft - 138 million euros.

The health fund's deficit of around 3.49 billion euros in 2020 is mainly due to cyclical shortfalls in income and the compensation payments made to service providers that were not compensated by the federal government.

To cope with the COVID19 pandemic, around 12.2 billion euros were made available from the health fund's liquidity reserve last year. This includes, among other things, compensation payments for hospital beds that have been kept free, compensation payments for newly created intensive care treatment options, for preventive and rehabilitation facilities and drug providers, as well as expenses for corona tests and protective masks. The federal government reimbursed around 9.9 billion euros, including about 9.4 billion euros, for the hospital beds that were kept free.

The health insurance companies' expenses for services and administrative costs rose by 4.0% in 2020. The service expenditures increased by 4.0%, the administrative costs by 4.8%.

The final financial results of the health insurance for 2020 and the data for the first quarter of 2021 will be available in mid-June 2021.

The full details in German can be found here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.

The latest related news

23

Mar 2022

In late January 2022, Swedish Medical Technologies Product (MTP) Council issued an updated version of recommendations regarding gene expression analysis for decision-making on the adjuvant breast cancer treatment, initially published in November 2021. The recommendation to the regions remains the same. The changes were only concerned with the clarification of some facts.

Read more

22

Mar 2022

On February 17, 2022, the Federal Joint Committee (G-BA) has decided to include the method of matrix-associated autologous chondrocyte implantation (M-ACI) on the knee joint in the case of symptomatic cartilage damage in the lists of reimbursed procedures in the hospital and ambulatory settings.

Read more

18

Mar 2022

On February 22, 2022, a repository of innovative acts outside the nomenclature of biology and anatomopathology (RIHN) and a Supplementary list of IVD tests were published. Minor changes were introduced in the 2022 RIHN list.

Read more

16

Mar 2022

In February 2022, Swedish Medical Technologies Product (MTP) Council issued an updated recommendation on FreeStyle Libre for continuous glucose monitoring in type 2 diabetes (T2D). The initial recommendations were published by NT Council in 2018 and updated by MTP Council in 2020 to include FreeStyle Libre 2. In the 2022 update, MTP Council decreased the Hba1c limit from 70 to 60 mmol/mol and added a statement on lifestyle changes and treatment optimization with non-insulin antidiabetic drugs.

Read more

14

Mar 2022

In February 2021, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclature for private payers in England, published Bulletins 0182 and 0079 with changes to be implemented no later than April 10, 2022. Three new procedure codes concerned robotic surgery in orthopaedic area, spinal procedures, and ophthalmology, and five new diagnostic codes were introduced.

Read more